title: [Burkholderia cepacia persistence in patients with mucoviscidosis].
abstract: OBJECTIVE
  Study features of persistence of Burkholderia cepacia in mucoviscidosis patients.
  
  
  METHODS
  In the period from 2008 to 2009, 56 B. cepacia strains isolated from children with mucoviscidosis were obtained. 114 medical histories of children with mucoviscidosis from various age groups were analyzed. The developed algorithm for identification and typing including phenotype and molecular biology methods was used to identify B. cepacia bacteria. Strain genotyping was carried out by RAPD-PCR with random oligonucleotide primer as well as pulse-electrophoresis.
  
  
  RESULTS
  Persistence of associations ofmicroogranisms in 59.4% of cases was established to be the feature of persistent infection in mucoviscidosis. The feature of persistence of B. cepacia strains in patients with diagnosis ofmuco-viscidosis mixed form, severe course is persistence in association with Pseudomonas aeruginosa. B. cepacia bacteria that can persist in mucoviscidosis patients are characterized by resistance to many antibiotics. A prolonged (up to 1 year and 5 months) persistence of B. cepacia strains isolated from 1 patient was proven by using microflora monitoring of lower respiratory tract.
  
  
  CONCLUSIONS
  B. cepacia bacteria may colonize lower respiratory tract of mucoviscidosis patients, persist for a long time and be transmitted between patients.
authors.forename: M Iu
authors.initials: MIu
authors.lastname: Chernukha
authors.forename: I A
authors.initials: IA
authors.lastname: Shaginian
authors.forename: N I
authors.initials: NI
authors.lastname: Kapranov
authors.forename: G V
authors.initials: GV
authors.lastname: Alekseeva
authors.forename: N Iu
authors.initials: NIu
authors.lastname: Kashirskaia
authors.forename: L R
authors.initials: LR
authors.lastname: Avetisian
authors.forename: S Iu
authors.initials: SIu
authors.lastname: Semykin
authors.forename: G A
authors.initials: GA
authors.lastname: Danilina
authors.forename: S V
authors.initials: SV
authors.lastname: Polikarpova
authors.forename: N V
authors.initials: NV
authors.lastname: Pivkina
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D015373:Bacterial Typing Techniques; D019121:Burkholderia Infections / Q000150:complications / Q000188:drug therapy / Q000382:microbiology*; D016956:Burkholderia cepacia / Q000145:classification / Q000472:pathogenicity* / Q000502:physiology; D002648:Child; D003550:Cystic Fibrosis / Q000150:complications / Q000382:microbiology*; D016172:DNA Fingerprinting; D017931:DNA Primers; D004269:DNA, Bacterial / Q000032:analysis / Q000235:genetics*; D024901:Drug Resistance, Multiple, Bacterial; D006801:Humans; D010802:Phylogeny; D011552:Pseudomonas Infections / Q000150:complications / Q000188:drug therapy / Q000382:microbiology*; D011550:Pseudomonas aeruginosa / Q000502:physiology; D019105:Random Amplified Polymorphic DNA Technique; D012137:Respiratory System / Q000187:drug effects / Q000382:microbiology / Q000473:pathology
chemical_list: D000900:Anti-Bacterial Agents; D017931:DNA Primers; D004269:DNA, Bacterial